Effect of lactoferrin for vaginitis and cervicitis in obstetrics
- Conditions
- Vacterial vaginitis, threatened preterm birthVaginosis, Bacterial
- Registration Number
- JPRN-jRCTs021190020
- Lead Sponsor
- Miura Hiroshi
- Brief Summary
Oral administration of lactoferrin enteric coated tablets for vaginitis or cervicitis in pregnant women inproved the vaginal flora, but no statistically significant difference was observed in comparison with the control group. This is thought to be due to the small number of cases. Since there were no cases of spontaneous preterm birth, it was unclear whether oral administration of lactoferrin enteric coated tablets contributed to the prevention of preterm birth. There was no adverse events.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 8
1) Maternal age: 20 years old or older, under 50 years
2) Pregnant women who plan to deliver in our department
3) Patients who have been diagnosed with intractable vaginitis or cervicitis, and who have not improved their vaginal discharge findings with conventional treatment
If not gain consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Intractable vagus or cervical inflammation patients improve vaginal discharge findings by taking lactoferrin-enter-soluble tablets<br>2. Preterm Birth Rate of Pregnant Women With Lactoferrin Enter-Dissolved Tablets
- Secondary Outcome Measures
Name Time Method Evaluation of side effects and other safety caused by lactoferrin-enter-lytic tablets